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Figure 1. Kaplan Meier ﬁgure by AMC recovery by day 100.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S164myeloma remains an incurable malignancy. Allogeneic he-
matopoietic cell transplantation (AHCT) though sought as a
potential curative strategy, has not translated to improved
overall survival (OS) owing to a high incidence of transplant
related mortality. The objective of this study was to assess if
monocyte and lymphocyte count recovery at day 100 had
any prognostic value in this population.
Methods: We performed a retrospective analysis of patients
who underwent AHCT for multiple myeloma between 2002
and 2013 at a single institution. The primary endpoint of the
study was day 100 peripheral blood absolute lymphocyte
(ALC) and monocyte count (AMC) post-AHCT on overall
survival (OS). Other patient, disease and transplant related
factors were also evaluated. An ALC >¼ 500/mL and AMC
>¼300/mL were used as cut-offs based on published data. OS
was deﬁned from the time of transplantation to last follow-
up or death due to any cause. OS estimates were determined
using the Kaplan-Meier estimator. Cox proportional hazards
model was used for multivariate analysis.
Results: 78 patients underwent AHCT for MM at our insti-
tution. Patient, disease and transplant characteristics are
reported in Table 1. Eight patients were excluded from the
survival and multivariate analysis owing to death prior to
day 100 or because of missing day 100 counts. On
multivariate analysis, only day 100 AMC <300 /mL was
associated with increased mortality (Table 2). ALC recovery
>¼500/mL at day 100, while signiﬁcant on univariate
analysis, was not signiﬁcant on multivariate analysis. Figure
1 shows the Kaplan-Meier survival ﬁgure for the cohort
that achieved an AMC >¼300 (blue) versus <300 (red),
log-rank p-value <0.0001.
Conclusions: In this heterogeneous cohort of multiple
myeloma patients who underwent AHCT, an AMC recovery of
>¼300/mL was associated with improved survival.Table 1
Characteristic Total, N¼78 (%)
Median age at transplant, years (range) 53 (23-69)
Median time from diagnosis to transplant,
months (range)
12 (7-81)
Gender
-Male 50 (64)
International Staging System
-I 27 (35)
-II 21 (27)
-III 28 (36)
-Missing 2 (2)
Disease Status at Transplant
-sCR, CR or VGPR 25 (32)
-PR 48 (62)
-Stable or Progressive disease 5 (6)
Donor type
-Related* 70 (90)
-Unrelated 8 (10)
Type of transplant
-Myeloablative 11 (14)
-Non-myeloablative 67 (86)
Chronic GVHD
-Present 29 (37)
-Absent 49 (63)
Median follow up of surviving patients,
months (range)
49.4 (2.3e129.3)
Table 2
Multivariate analysis of factors associated with mortality
Variable Relative risk (95% conﬁdence interval) p-value
Day 100 AMC 0.0002
-300/mL 1.0
-<300/mL 4.6 (2.1e10.2)203
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T-Follicular Helper Cells (TFH) interact with B-cells in the
germinal center to support B-cell proliferation, differentia-
tion and immunoglobulin gene class switch. TFH have been
reported to alter B-cell homeostasis in autoimmune diseases
(Morita et al, Immunity 2011) and to contribute to murine
chronic graft-vs.-host-disease (GVHD) (Flynn et al, Blood
2014). However, the role of TFH in immune reconstitution
and GVHD after human hematopoietic stem cell trans-
plantation (HSCT) has not been studied. Although TFH
function primarily in lymphoid tissues, these cells have also
been identiﬁed in peripheral blood. We analyzed fresh blood
samples from 98 patients obtained 2 to 97 months after
HSCT, and 11 Healthy Donors (HD). We deﬁned circulating
TFH (cTFH) as CD4+CD45RA-CXCR5+ T-cells. cTFH were then
subdivided into Th1, Th2, Th17 subsets (Th1: CXCR3+CCR6-,
Th2: CXCR3-CCR6-, Th17: CXCR3-CCR6+) as previously
described (Morita et al).
Analysis of patient peripheral blood revealed a progressive
increase in the cTFH absolute count from 2months to 2 years
after HSCT, which then reached a plateau. Nevertheless, cTFH
counts remained below normal values when compared with
HD throughout this period, and only reached normal levels 2
years after HSCT in parallel with recovery of total CD4+ Tcells
(Figure 1). In contrast, the fraction of cTFH within the CD4 T
cell compartment reached normal values within 6 months
after HSCT and remained stable.
To study the role of cTFH in cGVHD, we studied 71 patients
(excluding patients receiving prednisone >30mg/day, ritux-
imab or IL-2). In patients with active cGVHD, cTFH frequency
(median 8.78% vs. 10.5% of CD4+ T-cells, p¼0.0065) and cTFH
absolute counts (48.75 vs. 38.3/mL, p¼0.07) were decreased
compared with patients without cGVHD. cTFH subsets are
reported to have different functional capacities and this was
conﬁrmed by purifying and culturing each subset with naive
B-cells. In HD, we observed that only Th2 and Th17 subsets of
cTFH promoted B-cell IgG and IgM secretion (Figure 2). In
Figure 3: Comparison of Th2+Th17 cTFH (Left) and (Th2+Th17)/Th1 cTFH ratio (Right) in patients without cGVHD (N¼38) and with cGVHD (N¼33).
Figure 1. (Left) Recovery of tTFH and CD4+ T-cells/mL) after HSCT. (Right) Frequencies of cTFH in the CD4+ T-cell gate beginning 2 months after HSCT. Number of
patients analyzed for each time point is indicated below the graph. Dashed lines represent the median values from 11 Healthy Donors (90% CI plotted in light red and
light grey for the respective population).
Figure 2. Assessment of B-tell helper function in cTFH subsets. cTFH (CD4+CD45RA-CXCR5+) and non-cTFH (CD4+CD45RA-CXCR5-) T cell subsets were puriﬁed by
ﬂow cytometric cell sorting. IgG (left) and IgM (Right) production was measured in supernatants? after 12-day co-culture of puriﬁed T-cell subsets with naive B-cells
stimulated with Staphylococcal Enterotoxin B.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S165cGVHD patients, we observed a selective decrease of the Th1
compartment in the cTFH subset (16.2% and 10.9% for No vs.
cGVHD, p¼0.034), and relative increase of both Th2 and Th17
cTFH (Th2+Th17¼ 71.15 and 78.1% respectively, p¼0.07)
leading to a greater (Th2+Th17)/Th1 ratio (p¼0.044) (Figure
3). We did not ﬁnd any differences in cTFH subsets when
comparing Mild vs. Moderate and Severe cGVHD. To further
characterize cTFH, we analyzed BCL-2 and CD95 apoptosis
pathways. Th2 and Th17 cTFH subsets appeared to express
lower levels of CD95 and higher levels of BCL-2 compared to
Th1 cTFH.
Increased representation of Th2 and Th17 cTFH subsets
that are relatively resistant to apoptosis may be amechanismthat promotes B-cell deregulation and pathologic antibody
production in patients with cGVHD. Targeting Th2/Th17 cTFH
or TFH-B cell interactions may provide novel therapies in
patients with cGVHD.204
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